Posted by Michael Wonder on 19 Jul 2022
Daewoong's idiopathic pulmonary fibrosis drug gets FDA's fast track status
19 July 2022 - Daewoong Pharmaceutical said that the US FDA had granted fast track designation to its idiopathic pulmonary fibrosis therapy, DWN12088.
DWN12088 suppresses excessive generation of collagen, the cause of fibrosis, by reducing prolyl tRNA synthetase protein's effect on collagen production, according to Daewoong. The drug also won an orphan drug designation status from the FDA to treat idiopathic pulmonary fibrosis in August 2019.
